Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Brox-DX is a combination oral syrup developed by RH-Pharma, primarily indicated for the symptomatic relief of dry cough, nasal congestion, and allergic symptoms associated with the common cold or upper respiratory tract infections. It contains three active pharmaceutical ingredients: dextromethorphan hydrobromide, chlorpheniramine maleate, and phenylephrine hydrochloride. Dextromethorphan hydrobromide is a centrally acting antitussive that suppresses the cough reflex by acting on the cough center in the medulla. Chlorpheniramine maleate is a first-generation alkylamine antihistamine that provides relief from allergic symptoms such as sneezing, watery eyes, and runny nose by antagonizing H1 receptors. Phenylephrine hydrochloride is a sympathomimetic amine that acts as a nasal decongestant by stimulating alpha-1 adrenergic receptors, leading to vasoconstriction of the nasal mucosa and reduction of swelling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorpheniramine + dextromethorphan + phenylephrine.